Ventripoint Diagnostics Ltd. (VPTDF)

OTCMKTS · Delayed Price · Currency is USD
0.1091
-0.0009 (-0.79%)
Jul 21, 2025, 1:07 PM EDT
-29.46%
Market Cap18.25M
Revenue (ttm)115.83K
Net Income (ttm)-3.26M
Shares Outn/a
EPS (ttm)-0.02
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,050
Average Volume59,734
Open0.1067
Previous Close0.1100
Day's Range0.1051 - 0.1109
52-Week Range0.0497 - 0.1645
Beta0.13
RSI53.97
Earnings DateAug 29, 2025

About Ventripoint Diagnostics

Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. The company offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient’s heart chambers. It also provides VMS+ software, a 2D and 3D ultrasound models. In addition, it develops a suite of applications for various heart diseases and imaging modalities, in... [Read more]

Sector Healthcare
CEO Hugh MacNaught
Country Canada
Stock Exchange OTCMKTS
Ticker Symbol VPTDF
Full Company Profile

Financial Performance

In 2024, Ventripoint Diagnostics's revenue was 95,172, an increase of 93.51% compared to the previous year's 49,183. Losses were -4.92 million, 0.98% more than in 2023.

Financial numbers in CAD Financial Statements

News

Ventripoint to Issue Shares for Payment of Debenture Interest

Toronto, Ontario – TheNewswire - June 30, 2025 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”, ( TSXV:VPT) announces it will satisfy debenture interest payment obligations with...

21 days ago - TheNewswire

Ventripoint Partners with Fournel Advisory

Toronto, Ontario – TheNewswire - June 17, 2025 – Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) is pleased to announce that it has entered into an advisory agreem...

4 weeks ago - TheNewswire

Ventripoint Issues Option Grants and Reports Exercise of Options

Toronto, Ontario – TheNewswire – June 17, 202 5 - Ventripoint Diagnostics Ltd. (“ Ventripoint  ” or the “  Corporation  ”) (TSXV:VPT, OTC:VPTDF) is providing an update on options.  On March 12, 2025, ...

4 weeks ago - TheNewswire

Ventripoint to Exhibit at the 58th Annual Meeting of the Association for European Paediatric and Congenital Cardiology

Toronto, Ontario – TheNewswire – May 28, 2025 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) is pleased to announce its participation in the 58th Annual Meeting...

7 weeks ago - TheNewswire

Ventripoint Expands Advisory Board with addition of Ultrasound AI Executive

Toronto, Ontario – TheNewswire - April 30, 2025 – Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) has increased the depth of its commercial experience with the add...

2 months ago - TheNewswire

Ventripoint Provides Corporate Update and Announces Shareholder Teleconference

Toronto, Canada — April 10, 2025 — TheNewswire - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) , a leading provider of innovative cardiac diagnostic solutions, i...

3 months ago - TheNewswire

Ventripoint Appoints Nicolas Coutin to Oversee Clinical Affairs

Toronto, Ontario – TheNewswire - April 8, 2025 – Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) today announced that it has appointed Nic Coutin, PhD. to oversee ...

3 months ago - TheNewswire

Ventripoint Makes Application to Amend Warrants

Toronto, Ontario, April 3, 2025 – TheNewswire - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT; OTC:VPTDF)  announces that it has made an application to the TSX Venture E...

3 months ago - TheNewswire

Ventripoint Diagnostics Publishes Whitepaper on the Use of AI in Whole-Heart Analysis

Toronto, Ontario – TheNewswire - March 24, 2025 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT; OTC:VPTDF) is pleased to announce the release of a whitepaper comparing ...

4 months ago - TheNewswire

Ventripoint Announces Closing of $500,000 Non-Brokered Convertible Debenture Unit Private Placement

Toronto, Ontario, March 21, 2025 – TheNewswire - Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”, TSXV:VPT) announces the closing of its previously announced (see press release of...

4 months ago - TheNewswire

Ventripoint Announces Non-Brokered Convertible Debenture Units Private Placement

Toronto, Ontario – TheNewswire - March 14, 2025 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”) , ( TSXV:VPT) announces a non-brokered private placement of up to CDN$500,000 (...

4 months ago - TheNewswire

Ventripoint Diagnostics Announces U.S. FDA 510(k) Clearance for VMS+(TM) 4.0 Automated Radiological Image Processing Software/System

Toronto, Ontario  - TheNewswire - February 27, 2025 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT; OTC:VPTDF) is pleased to announce that it has received U.S. Food and...

5 months ago - TheNewswire

Ventripoint Issues Option Grants and Reports Exercise of Options

Toronto, Ontario – TheNewswire – February 11, 2024  - Ventripoint Diagnostics Ltd. (“ Ventripoint  ” or the “  Corporation  ”)(TSXV:VPT, OTC:VPTDF) announces that on January 20, 2025, the Corporation ...

5 months ago - TheNewswire

Ventripoint Diagnostics issues shares for payment of debenture interest

Ventripoint Diagnostics issues shares to pay interest on convertible debentures, with shares priced at $0.11 subject to TSXV approval.

6 months ago - Seeking Alpha